Pharmaceutical Substances - Version 4.5
The version 4.5 of Pharmaceutical Substances was launched in December 2018.
Pharmaceutical Substances 4.5 contains 15 new APIs and a total of 40,813 structures, 12,137 reactions, and 2,703 active pharmaceutical ingredients.
- Elagolix sodium
- Fostamatinib Disodium
“The increased speed of regulators allowing breakthrough therapy entering the market is reflected by currency of our compendial update with 29 new entries in total for 2018.
The new release 4.5 covers 15 new APIs and comprises a lot of innovative drugs with anticipated blockbuster potential.
Amongst them are Elagolix, the first peptidomimetic LHRH-antagonist against endometriosis induced pain and Tezacaftor as new respiratory stimulant against cystic fibrosis.
Furthermore, the update contains various kinase inhibitors like Binimetinib and Encorafenib for oncology as well Fostamatinib and Avathrombopag for treatment of thrombocytopenia.
Progress was further achieved with novel antivirals for HIV and HCV therapy like Bictegravir and Dasabuvir as well as new oral antidiabetics like Ertuglifloxin and Ipraglifloxin.
This latest release also describes Plazomycin, Cariprazine, Fosnetupitant, Netarsudil and Octenidine for various indications.”
Authors Prof. Axel Kleemann, Prof. Bernhard Kutscher, Dr. Dietmar Reichert
Thieme Chemistry Marketing Phone:+49-711-8931-771 Fax:+49-711-8931-777 E-Mail